Advanced Oncotherapy PLC Change of Adviser (5478O)

TIDMAVO

RNS Number : 5478O

Advanced Oncotherapy PLC

08 November 2016

8 November 2016

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Appointment of Joint Broker

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces the appointment of Stifel Nicolaus Europe Limited as Joint Broker to the Company, with immediate effect. Stockdale Securities remains Nominated Adviser to the Company.

 
  Advanced Oncotherapy Plc                   www.avoplc.com 
  Dr Michael Sinclair, Executive      Tel: +44 20 3617 8728 
   Chairman 
   Nicolas Serandour, CEO 
 
   Stockdale Securities               Tel: +44 20 7601 6100 
    (Nomad & Joint Broker) 
  Antonio Bossi / David 
   Coaten 
 
   Stifel Nicolaus Europe             Tel: +44 20 7710 7600 
    Limited (Joint Broker) 
  Jonathan Senior / Ben 
   Maddison 
 
   Walbrook PR (Financial          Tel: +44 20 7933 8780 or 
    PR & IR)                             avo@walbrookpr.com 
  Paul McManus / Anna Dunphy        Mob: +44 7980 541 893 / 
                                      Mob: +44 7876 741 001

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

This information is provided by RNS

The company news service from the London Stock Exchange

END

APPKMMGMNNNGVZM

(END) Dow Jones Newswires

November 08, 2016 02:01 ET (07:01 GMT)

Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2024 to May 2024